These target genes are particularly sensitive to DOT1L inhibition, which provides a new molecular rationale for the specificity of DOT1L or Menin inhibition in MLL-AF4 leukemias, and the possibility of combining this with drugs that target less sensitive spreading targets such as those that target BCL-2. The gene discussed is BCL2; the disease is leukemia.